Apollomics Advances Vebreltinib c-MET Inhibitor with Phase 2/3 IND Submission for NSCLC Treatment

Key Takeaways

• Apollomics has dosed over 600 patients and 170 healthy volunteers with vebreltinib, demonstrating significant clinical experience with the c-MET inhibitor
• Phase 2/3 IND submission planned for vebreltinib combination therapy with EGFR inhibitor in U.S. and select Asian markets for NSCLC treatment
• Multiple Phase 2 studies ongoing to advance global development of the potentially best-in-class and first-in-class c-MET inhibitor

---

Apollomics Advances c-MET Inhibitor Development

Apollomics reported significant clinical progress for its lead oncology asset vebreltinib during its full year 2025 financial results announcement on April 27, 2026. The biotechnology company highlighted key milestones for the c-MET inhibitor, including extensive patient dosing experience and regulatory advancement plans.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Extensive Clinical Experience Demonstrates Safety Profile

The company has achieved substantial clinical experience with vebreltinib, having dosed more than 600 patients and 170 healthy volunteers across multiple clinical trials. This extensive dosing history provides valuable safety and efficacy data as the company advances toward later-stage development.

Verbreltinib is positioned as a highly potent, de-risked c-MET inhibitor with potential best-in-class and first-in-class characteristics. The c-MET pathway plays a crucial role in cancer cell growth and metastasis, making it an attractive target for oncology therapeutics.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Regulatory Advancement in Key Markets

Apollomics plans to submit a Phase 2/3 Investigational New Drug (IND) application for vebreltinib development in combination with an EGFR inhibitor. This combination approach targets non-small cell lung cancer (NSCLC) patients in the United States and select Asian countries.

The combination strategy addresses a significant medical need, as EGFR-mutated NSCLC patients often develop resistance to EGFR inhibitors alone. Adding a c-MET inhibitor like vebreltinib could potentially overcome this resistance mechanism and improve patient outcomes.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for pharmaceutical intelligence pricing, access, and launch sequencing.

Multiple Phase 2 Studies Support Global Strategy

The company continues advancing multiple Phase 2 studies to support vebreltinib’s global development strategy. These ongoing trials are designed to establish the drug’s efficacy profile across different patient populations and treatment combinations.

The NSCLC market represents a significant commercial opportunity, with the global market expected to continue growing as new targeted therapies demonstrate improved outcomes over traditional chemotherapy approaches.

---

Frequently Asked Questions

What makes vebreltinib different from other c-MET inhibitors?

Vebreltinib is described as a highly potent, de-risked c-MET inhibitor with potential best-in-class and first-in-class characteristics, though specific differentiation details were not provided in the announcement.

When will vebreltinib be available for NSCLC patients?

Apollomics is planning Phase 2/3 IND submission for the combination therapy. If successful, the drug would still need to complete Phase 2/3 trials and gain regulatory approval, which typically takes several years.

Why combine vebreltinib with an EGFR inhibitor for NSCLC treatment?

The combination targets resistance mechanisms that often develop with EGFR inhibitor monotherapy in NSCLC patients, potentially providing better outcomes than single-agent treatment.

Related coverage

• FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
• FDA approves Merck’s Keytruda for adjuvant NSCLC treatment
• Lundbeck Advances Lu AG09222 After Phase 2 Migraine Data